Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 888 | 927 | 907 | 1120 | 1169 | 2207 |
Fund Return | -11.16% | -7.3% | -9.27% | 3.85% | 3.17% | 8.24% |
Place in category | 162 | 55 | 205 | 128 | 48 | 9 |
% in Category | 44 | 31 | 54 | 43 | 26 | 4 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
American Growth Portfolio B Acu | 8.27B | 16.65 | 3.66 | 13.17 | ||
American Growth Portfolio A Acu | 8.27B | 19.12 | 5.28 | 14.18 | ||
American Growth Portfolio C Acu | 8.27B | 18.67 | 4.81 | 13.67 | ||
American Growth Portfolio I Acc | 8.27B | 19.92 | 6.13 | 15.10 | ||
American Growth Portfolio S1 Acc | 8.27B | 20.17 | 6.38 | 15.41 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
European Value Fund D2u | 130.45M | 11.86 | 8.40 | 6.91 | ||
LU0171281834 | 77.52M | 10.70 | 7.06 | 5.58 | ||
European Equity Portfolio I Accu | 395.43M | 21.67 | 12.18 | 10.15 | ||
European Equity Portfolio A Acc | 395.43M | -11.83 | 2.65 | 6.87 | ||
European Equity Portfolio C Acu | 395.43M | -12.06 | 2.19 | 6.40 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Shell | GB00BP6MXD84 | 5.90 | 30.72 | -0.52% | |
Nestle | CH0038863350 | 5.57 | 76.36 | +0.69% | |
Roche Holding Participation | CH0012032048 | 4.71 | 252.50 | +0.44% | |
Sanofi | FR0000120578 | 2.94 | 92.31 | +0.64% | |
Deutsche Telekom AG | DE0005557508 | 2.79 | 29.910 | +0.44% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Sell | Neutral |
Technical Indicators | Strong Sell | Strong Sell | BUY |
Summary | Strong Sell | Strong Sell | Neutral |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review